| Project | Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Regulatory Approval |
|---|---|---|---|---|---|---|
| Motixafortide (BL-8040) | HSC Mobilization in Multiple Myeloma (NDA Submitted to FDA) | |||||
| Pancreatic Cancer 1L | ||||||
| Pancreatic Cancer 1L (Investigator Initiated Study, In Combination with Libtayo) | ||||||
| HSC Mobilization in Sickle Cell Disease (Investigator Initiated Study) | ||||||
| AGI-134 | Solid tumors |
Motixafortide (BL-8040)
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is ...
INDICATIONS : 2
CLINICAL STUDIES : 13
AGI-134
AGI-134 is a synthetic alpha-Gal glycolipid in development for solid tumors that is highly differentiated from other cancer ...
